Thomas Charles Heineman insider trades: Oncolytics Biotech (ONCY) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | ONCY | ↑ Buy | 12,132 | $0.83 | $10K | Direct | Feb 13, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ONCY insiders
Open-market trades in the last 12 months
About Thomas Charles Heineman's insider trades
Thomas Charles Heineman is Chief Medical Officer at Oncolytics Biotech (ONCY). Since Feb 12, 2026, Thomas has reported 1 open-market purchase worth $10K and no sales on SEC Form 4. In the last 12 months: 1 buy ($10K).
Their filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONCY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.